Accesswire
19 Jun 2026, 22:00 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Onco-Innovations successfully completed a 300g scale-up batch of the API for its drug candidate ONC010 with 99.3% purity. — Proving manufacturing scalability and high purity is a critical technical derisking milestone necessary to move toward human clinical trials.
+0.60The completed API batch will support ongoing IND-enabling activities and the path toward First-in-Human evaluation. — Directly advances the timeline for regulatory filing (IND), bringing the company closer to the value-inflection point of clinical data.
+0.40The company appointed Dave Antony as the new Chief Financial Officer and Corporate Secretary, replacing Nico Mah. — C-suite changes are standard operational updates and generally have neutral to low impact unless accompanied by negative context.
+0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The company achieved a significant manufacturing milestone with high-purity API scale-up for its lead drug candidate and appointed a new CFO.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
5h ago
